A major limiting factor in anti-neoplastic therapy is the failure of some tumor types to respond to anticancer treatments, and the appearance of resistant cell populations in originally responsive malignancies upon relapse. There is a large body of evidence that genetic changes leading to increased cap-dependent translation are accompanied by cancer cell chemoresistance and are associated with a poor prognosis. We have recently discovered that inhibiting assembly of the cap-dependent translation initiation apparatus eIF4F, (a trimolecular complex of eIF4G, eIF4A and eIF4E) in Ras Vl2 transformed cells by transfer of the gene encoding translational repressor 4E-BPl (which sequesters eIF4E, the 5? mRNA cap binding protein), sensitizes these cells to non-genotoxic and genotoxic cytostatic drugs in vitro, and dramatically reduces their tumorigenicity. Most importantly from a therapeutic point of view, we have found that disruption of eIF4F assembly specifically activates apoptosis in cancer cells, but not in non-transformed cells, identifying eIF4F as a potential novel molecular target for anticancer drug discovery . Thus, here we propose to test the hypothesis that phosphoramidate nucleotide derivatives that repress cap-dependent translation initiation by interfering with the interaction between the 5? rnRNA cap and eIF4E will activate apoptosis in a wide spectrum of cancer cells with an upregulated translation apparatus; and sensitize them to safe doses of chemotherapeutic agents without harming desirable bystander cells.
Our Aims i nclude:
Aim 1. Synthesize a library of nucleotides predicted to inhibit binding of eIF4E to the 5? rnRNA cap;
Aim 2. Test candidate compounds in an ordered series of high and medium throughput in vitro assay systems;
Aim 3. Utilize preclinical models of breast and lung cancer to test the most promising compound (based on Aim 2 results) for its ability to collaborate with well-tolerated doses of available cancer therapeutics to inhibit xenograft growth in athymic mice. To achieve these aims, we have assembled an experienced investigative team committed to anticancer drug discovery .

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA091220-04
Application #
6743142
Study Section
Special Emphasis Panel (ZCA1-SRRB-D (J3))
Program Officer
Arya, Suresh
Project Start
2001-06-14
Project End
2006-05-31
Budget Start
2004-06-01
Budget End
2006-05-31
Support Year
4
Fiscal Year
2004
Total Cost
$415,856
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Jia, Yan; Chiu, Ting-Lan; Amin, Elizabeth A et al. (2010) Design, synthesis and evaluation of analogs of initiation factor 4E (eIF4E) cap-binding antagonist Bn7-GMP. Eur J Med Chem 45:1304-13
Ghosh, Brahma; Benyumov, Alexey O; Ghosh, Phalguni et al. (2009) Nontoxic chemical interdiction of the epithelial-to-mesenchymal transition by targeting cap-dependent translation. ACS Chem Biol 4:367-77
Ghosh, Phalguni; Cheng, Jilin; Chou, Tsui-Fen et al. (2008) Expression, purification and characterization of recombinant mouse translation initiation factor eIF4E as a dihydrofolate reductase (DHFR) fusion protein. Protein Expr Purif 60:132-9
Jacobson, Blake A; Alter, Michael D; Kratzke, Marian G et al. (2006) Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo. Cancer Res 66:4256-62
Ghosh, Phalguni; Park, Chunkyung; Peterson, Mark S et al. (2005) Synthesis and evaluation of potential inhibitors of eIF4E cap binding to 7-methyl GTP. Bioorg Med Chem Lett 15:2177-80
Avdulov, Svetlana; Li, Shunan; Michalek, Van et al. (2004) Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 5:553-63
Li, Shunan; Perlman, David M; Peterson, Mark S et al. (2004) Translation initiation factor 4E blocks endoplasmic reticulum-mediated apoptosis. J Biol Chem 279:21312-7
Ribas, A; Butterfield, L H; McBride, W H et al. (1999) Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells. Cancer Gene Ther 6:523-36